Genscript Biotech Corporation (G51) — Cash Flow Quality Index
Genscript Biotech Corporation (G51) has a Cash Flow Quality Index of 0.03x as of December 2024. Operating cash flow of €75.65 Million is below net income of €2.96 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore Genscript Biotech Corporation (G51) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Genscript Biotech Corporation Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Genscript Biotech Corporation across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see G51 cash flow conversion.
Annual Cash Flow Quality Index for Genscript Biotech Corporation (2016–2024)
Year-by-year earnings quality comparison for Genscript Biotech Corporation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | €75.65 Million | €2.96 Billion | ▼ -99.8% |
| 2018 | 14.50x | €307.66 Million | €21.22 Million | ▲ +1672.8% |
| 2017 | 0.82x | €21.37 Million | €26.12 Million | ▼ -35.7% |
| 2016 | 1.27x | €33.27 Million | €26.17 Million | — |